ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 70 filers reported holding ALPINE IMMUNE SCIENCES INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $520,689 | +8.7% | 45,475 | -2.4% | 0.00% | +50.0% |
| Q2 2023 | $478,976 | +14.4% | 46,593 | -14.1% | 0.00% | 0.0% |
| Q1 2023 | $418,710 | -2.3% | 54,237 | -7.0% | 0.00% | 0.0% |
| Q4 2022 | $428,564 | +3.5% | 58,308 | +1.4% | 0.00% | -33.3% |
| Q3 2022 | $414,000 | -3.0% | 57,506 | +14.6% | 0.00% | 0.0% |
| Q2 2022 | $427,000 | +68.1% | 50,189 | +77.2% | 0.00% | +200.0% |
| Q1 2022 | $254,000 | -3.8% | 28,316 | +48.8% | 0.00% | 0.0% |
| Q4 2021 | $264,000 | – | 19,026 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 3,056,420 | $22,006,000 | 19.85% |
| Decheng Capital Management III (Cayman), LLC | 6,708,288 | $48,300,000 | 17.51% |
| GREAT POINT PARTNERS LLC | 3,448,521 | $24,829,000 | 5.98% |
| Omega Fund Management, LLC | 2,029,580 | $14,613,000 | 5.35% |
| Paradigm Biocapital Advisors LP | 2,214,722 | $15,946,000 | 2.13% |
| Frazier Life Sciences Management, L.P. | 2,985,757 | $21,497,000 | 1.66% |
| COMMODORE CAPITAL LP | 1,325,000 | $9,540,000 | 1.53% |
| Octagon Capital Advisors LP | 1,225,000 | $8,820,000 | 1.52% |
| RA Capital Management | 4,356,632 | $31,368,000 | 0.67% |
| TCG Crossover Management, LLC | 254,569 | $1,833,000 | 0.55% |